The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 48 (Issue 1227) January 30, 2006

www.medicalletter.org

IN THIS ISSUE

UPDATE

Influenza Resistance to Amantadine and Rimantadine

Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005; 47:93) mentioned possible use of amantadine (Symmetrel, and others) and rimantadine (Flumadine, and others), but warned that the incidence of resistance has increased substantially. The CDC recently issued a Health Alert (www.cdc.gov) saying that current evidence indicates that a high proportion of circulating influenza A viruses in the US are now resistant to amantadine and rimantadine and they should not be used for this indication, at least this year.

The Medical Letter®

On Drugs and Therapeutics

EDITOR: Mark Abramowicz. M.D.

DEPUTY EDITOR: Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University

DIRECTOR OF DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. ADVISORY BOARD:

Jules Hirsch, M.D., Rockefeller University

James D. Kenney, M.D., Yale University School of Medicine Richard B. Kim, M.D., Vanderbilt School of Medicine

Gerald L. Mandell, M.D., University of Virginia School of Medicine Hans Meinertz, M.D., University Hospital, Copenhagen

Dan M. Roden, M.D., Vanderbilt School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba

Neal H. Steigbigel, M.D., New York University School of Medicine EDITORIAL FELLOWS:

Monika K. Shah, M.D., Columbia University College of Physicians and Surgeons, Jane Gagliardi, M.D., Duke University Medical Center SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard ASSISTANT EDITORS: Cynthia Macapagal Covey, Tracy Shields MANAGING EDITOR: Susie Wong

PRODUCTION COORDINATOR: Chervi Brown

VP FINANCE & OPERATIONS: Yosef Wissner-Levy

Founded in 1959 by

Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission

Subscription Services

Mailing Address:

The Medical Letter Inc. 1000 Main Street

New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500 Web Site: www.medicalletter.org
E-mail: custserv@medicallett Fax: 914-632-1733

E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$89; 2 years - \$151; 3 years - \$214. \$44.50 per year for students, interns, residents and fellows in the US and Canada. CMF: \$44 for 26 credits.

E-mail site license inquiries to:

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions.

Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted

Copyright 2006. ISSN 1523-2859